Canada markets closed

ProQR Therapeutics N.V. (PRQR)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.2899-0.0901 (-3.79%)
At close: 04:00PM EDT
2.2100 -0.08 (-3.49%)
After hours: 07:58PM EDT

ProQR Therapeutics N.V.

Zernikedreef 9
Leiden 2333 CK
Netherlands
31 88 166 7000
https://www.proqr.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees156

Key Executives

NameTitlePayExercisedYear Born
Dr. Domenico Valerio Ph.D.Founder & Independent Chairman of Supervisory Board80.16kN/A1956
Mr. Daniel Anton de BoerFounder, CEO & Member of Management Board1.29MN/A1983
Mr. Rene K. BeukemaChief Corporate Development Officer, General Counsel & Member of Management Board991.11kN/A1964
Dr. Gerard PlatenburgCo-Founder & Chief Scientific Officer23.83kN/A1964
Mr. Jurriaan DekkersChief Financial OfficerN/AN/A1976
Ms. Sheila SponseleeChief People & Operations OfficerN/AN/A1984
Ms. Sarah Cue KielyVice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Ms. Sandra van der KolkJunior Financial ControllerN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Corporate Governance

ProQR Therapeutics N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.